- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06177795
Increasing Screening for Cancer Using EHR-Nudges (I-SCREEN)
I-SCREEN: Increasing Screening for Cancer Using a Randomized Evaluation of EHR-based Nudges
Study Overview
Status
Conditions
Detailed Description
Cancer is a leading cause of mortality in the United States. While strong USPSTF guideline recommendations support appropriate screening for early detection and to avoid preventable deaths, breast cancer screening is often underutilized. Increasing breast cancer screening rates is challenging, in part, because it requires complementary decisions from clinicians (e.g., recommend and counsel patients about screening) and patients (e.g., to internalize risks and choose to complete screening). Presently, the lack of interventions directly targeting both clinicians' and patients' decision-making may underscore the relatively stagnant screening rates in the United States. There is a significant need to develop and scale low-cost interventions that increase breast cancer screening while simultaneously addressing the needs of high-risk patients and reducing disparities. Building upon prior work, the investigators propose to develop and test EHR-based clinician and patient nudges, with an additional intensified nudge to high-risk patients, to help increase screening mammography rates.
This study consists of two complementary and concurrent, cluster-randomized, pragmatic trials to be conducted at Penn and UH.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University/University Hospitals
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All patients must meet the following criteria to be eligible:
- Women between 40 and 74 years of age
- A scheduled new or return (non-urgent/sick) primary care visit at one of the study practices (Penn Trial) or with one of the study primary care providers (UH Trial)
- Are overdue and eligible for a mammogram per Health Maintenance
- Does not have a future scheduled mammogram appointment
For the Penn Trial patient intensification nudge, at least one of the following criteria must be met to be considered high risk and randomized to receive the intensification nudge:
- Medicare Insurance
- Medicaid Insurance
- No EHR patient portal account
- Zero log-ins to EHR patient portal in the previous year
Exclusion Criteria:
Patients will be excluded from the study if:
- History of bilateral mastectomy
- Have a mammogram exclusion modifier in Health Maintenance
- Have no phone number (home or mobile) listed in their chart (Penn Trial only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Penn: Control
Clinics randomized to the control arm will receive standard of care.
|
|
|
Experimental: Penn: Intervention
Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges.
Patient nudges will be post-visit text message reminders (standard messaging content).
Clinician nudges will be default pended orders.
|
Patients will be sent text message reminders 4 days and 14 days after their primary care visit.
The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling.
The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter.
Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
|
|
Experimental: Penn: High Risk Intensification
Patients in the intervention clinics identified as high risk for noncompletion of mammogram will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm.
Patients in the high risk intensification arm will receive an additional bidirectional texting component.
|
Patients will be sent text message reminders 4 days and 14 days after their primary care visit.
The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling.
The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter.
Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit.
This intervention will query the patient about common questions or concerns about breast cancer screening.
The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
|
|
No Intervention: UH: Control
Primary care providers randomized to the control arm will receive standard of care.
|
|
|
Experimental: UH: Intervention
Primary care providers randomized to the intervention arm will receive default pended orders for a mammogram.
|
A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter.
Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients who complete a screening mammogram within 3 months after the visit
Time Frame: 3 months
|
The primary outcome is screening mammogram completion within 3 months after the first eligible primary care visit.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients who complete a screening mammogram within 6 months after the visit
Time Frame: 6 months
|
The secondary outcome is screening mammogram completion within 6 months after the first eligible primary care visit.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amol Navathe, MD, PhD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- UPCC 12022
- R33AG068947 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Post-visit patient text messaging
-
Abramson Cancer Center at Penn MedicineNational Institute on Aging (NIA)Active, not recruitingBreast CancerUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA); University of WashingtonCompletedFlu | Behavior, Health | Flu VaccinationUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedFlu | Behavior, Health | Flu VaccinationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingFamily Member | Health Status UnknownUnited States
-
University of UtahBen B & Iris Margolis Private Foundation for Medical ResearchCompleted
-
Northwestern UniversityAllianceChicago; Cook County HealthActive, not recruitingGestational Diabetes Mellitus | Hypertension in Pregnancy | DysglycemiaUnited States
-
Mayo ClinicTerminatedObesityUnited States
-
Abramson Cancer Center at Penn MedicineActive, not recruitingColorectal CancerUnited States
-
University of Colorado, DenverNational Institute of Mental Health (NIMH)CompletedHIV InfectionsUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCOVID-19United States